DTx in rare diseases

There are 400M people worldwide suffering from Rare Diseases, however, it usually takes a long time to diagnose them accurately (e.g 5 years on average in the UK) and less than 10% of patients receive treatment. As a way to enable faster diagnosis and referral, diagnosis algorithms are increasingly being adopted to help GPs identify misdiagnosed and undiagnosed patients using EHRs. How can we leverage AI to establish new clinically validated digital biomarkers and novel disease predictors for rare diseases? Beyond the diagnosis use case, how can DTx solutions help improve treatment and disease management? The high diversity of rare diseases might hold off investments in the area; is addressing common unmet needs the right approach for DTx companies to make the market more alluring to digital health investors? Join the meeting to discuss the future of DTx in rare diseases with other thought leaders.